Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The investigators conducted a phase II, prospective, two-arm clinical study to explore the
efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion
therapy of potentially resectable advanced esophageal squamous cell carcinoma. This study
will provide more evidence for conversion treatment of initially unresectable locally
advanced esophageal squamous cell carcinoma and contribute to the development of treatment
guidelines for esophageal cancer.